Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 2
1986 1
1987 20
1988 4
1989 2
1990 12
1991 7
1992 24
1993 4
1994 11
1995 7
1996 17
1997 12
1998 10
1999 21
2000 23
2001 40
2002 36
2003 30
2004 44
2005 50
2006 41
2007 58
2008 34
2009 21
2010 25
2011 28
2012 36
2013 40
2014 23
2015 24
2016 24
2017 16
2018 9
2019 11
2020 7
2021 7
2022 5
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Poole-Wilson PA, et al. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. Lancet. 2003. PMID: 12853193 Clinical Trial.
The composite endpoint of mortality or all-cause admission occurred in 1116 (74%) of 1511 on carvedilol and in 1160 (76%) of 1518 on metoprolol (0.94 [0.86-1.02], p=0.122). Incidence of side-effects and drug withdrawals did not differ by much between the two study groups. …
The composite endpoint of mortality or all-cause admission occurred in 1116 (74%) of 1511 on carvedilol and in 1160 (76%) of 1518 on …
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. Villanueva C, et al. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Lancet. 2019. PMID: 30910320 Clinical Trial.
Responders (HVPG-decrease 10%) were randomly assigned to propranolol (up to 160 mg twice a day) versus placebo and non-responders to carvedilol (25 mg/day) versus placebo. Doses were individually determined during an open-label titration period after which randomisation wa …
Responders (HVPG-decrease 10%) were randomly assigned to propranolol (up to 160 mg twice a day) versus placebo and non-responders to carv …
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. Packer M, et al. N Engl J Med. 1996 May 23;334(21):1349-55. doi: 10.1056/NEJM199605233342101. N Engl J Med. 1996. PMID: 8614419 Free article. Clinical Trial.

RESULTS: The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in risk attributable to carvedilol was 65 percent (95 percent confidence interval, 39 to 80 percent; P < 0.001). ...Worsening heart fai

…
RESULTS: The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in ri …
Effect of carvedilol on survival in severe chronic heart failure.
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Packer M, et al. N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201. N Engl J Med. 2001. PMID: 11386263 Free article. Clinical Trial.
RESULTS: There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent decrease in the risk of death with carvedilol (95 percent confidence interval, 19 to 48 percent; P=0.00013, unadjusted; P=0.0014, adjus …
RESULTS: There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent de …
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
Dargie HJ. Dargie HJ. Lancet. 2001 May 5;357(9266):1385-90. doi: 10.1016/s0140-6736(00)04560-8. Lancet. 2001. PMID: 11356434 Clinical Trial.
Analysis was by intention to treat. FINDINGS: Although there was no difference between the carvedilol and placebo groups in the number of patients with the primary endpoint (340 [35%] vs 367 [37%], hazard ratio 0.92 [95% CI 0.80-1.07]), all-cause mortality alone was lower …
Analysis was by intention to treat. FINDINGS: Although there was no difference between the carvedilol and placebo groups in the numbe …
Carvedilol.
[No authors listed] [No authors listed] Can Fam Physician. 1999 May;45:1199-202, 1205-9. Can Fam Physician. 1999. PMID: 10349064 Free PMC article. Clinical Trial.
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. ...When treatment is introduced very gradually, adverse effects (malaise) seem to be minor and infrequent. Carvedilol's place in the treatment of heart failure is not yet …
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. ...When treatment is introduced very graduall …
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Packer M, et al. Circulation. 2002 Oct 22;106(17):2194-9. doi: 10.1161/01.cir.0000035653.72855.bf. Circulation. 2002. PMID: 12390947 Clinical Trial.
Patients in the carvedilol group also spent 27% fewer days in the hospital for any reason (P=0.0005) and 40% fewer days in the hospital for heart failure (P<0.0001). ...More patients felt improved and fewer patients felt worse in the carvedilol group than in the …
Patients in the carvedilol group also spent 27% fewer days in the hospital for any reason (P=0.0005) and 40% fewer days in the hospit …
Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis.
Premkumar M, Rangegowda D, Vyas T, Khumuckham JS, Shasthry SM, Thomas SS, Goyal R, Kumar G, Sarin SK. Premkumar M, et al. J Clin Gastroenterol. 2020 Jul;54(6):561-568. doi: 10.1097/MCG.0000000000001219. J Clin Gastroenterol. 2020. PMID: 31305281 Clinical Trial.
BACKGROUND: Left ventricular diastolic dysfunction (LVDD) refers to impaired cardiac diastolic relaxation and may be improved by targeted heart rate reduction (THR). The authors evaluated whether a combination of carvedilol and ivabradine, an If channel blocker that reduce …
BACKGROUND: Left ventricular diastolic dysfunction (LVDD) refers to impaired cardiac diastolic relaxation and may be improved by targeted he …
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, Hawley CM, Isbel NM, Marshall MR, Pascoe EM, Pedagogos E, Pilmore HL, Snelling P, Stanton T, Tan KS, Tonkin AM, Vergara LA, Ierino FL. Roberts MA, et al. Kidney Blood Press Res. 2017;42(6):1033-1044. doi: 10.1159/000485589. Epub 2017 Dec 4. Kidney Blood Press Res. 2017. PMID: 29197871 Free article. Clinical Trial.
NTproBNP and hs-TnT correlated with GLS (Spearman's rho=0.34 [p=0.018] and rho=0.28 [p=0.049], respectively). Median change scores from baseline to 12 months did not differ significantly between participants with complete biomarker data randomized to carvedilol (n=1 …
NTproBNP and hs-TnT correlated with GLS (Spearman's rho=0.34 [p=0.018] and rho=0.28 [p=0.049], respectively). Median change scores fr …
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.
Park CS, Park JJ, Lee HY, Kang SM, Yoo BS, Jeon ES, Hong SK, Shin JH, Kim MA, Park DG, Kim EJ, Hong SJ, Kim SY, Kim JJ, Choi DJ. Park CS, et al. Cardiovasc Drugs Ther. 2023 Jun;37(3):529-537. doi: 10.1007/s10557-021-07238-3. Epub 2022 Jan 23. Cardiovasc Drugs Ther. 2023. PMID: 35066737 Clinical Trial.
However, it had a short half-life time mandating twice a day administration. We investigated whether slow-release carvedilol (carvedilol-SR) is non-inferior to standard immediate-release carvedilol (carvedilol-IR) in terms of clinical efficacy in patie …
However, it had a short half-life time mandating twice a day administration. We investigated whether slow-release carvedilol (carv …
727 results